Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689661 | 1.00 | KDM4E (0.52) | KDM4ESLC18A3GRIN2BGRIN1SPHK1 | |
| SCHEMBL7023319 | 1.00 | KDM4E (0.52) | KDM4ESLC18A3GRIN2BGRIN1SPHK1 | |
| SCHEMBL6841392 | 0.95 | KDM4E (0.56) | KDM4ESLC18A3GRIN2BGRIN1SPHK1 | |
| SCHEMBL6836225 | 0.95 | KDM4E (0.56) | KDM4ESLC18A3GRIN2BGRIN1SPHK1 | |
| SCHEMBL6840856 | 0.91 | KDM4E (0.54) | KDM4ESLC18A3GRIN2BGRIN1SPHK1 | |
| SCHEMBL6840853 | 0.91 | KDM4E (0.54) | KDM4ESLC18A3GRIN2BGRIN1SPHK1 | |
| SCHEMBL5689337 | 0.87 | SPHK1 (0.49) | KDM4EGRIN2BSPHK1 | |
| SCHEMBL5689334 | 0.87 | SPHK1 (0.49) | KDM4EGRIN2BSPHK1 | |
| SCHEMBL5690277 | 0.87 | KDM4E (0.52) | KDM4ESLC18A3GRIN2BGRIN1SPHK1 | |
| SCHEMBL5690271 | 0.87 | KDM4E (0.52) | KDM4ESLC18A3GRIN2BGRIN1SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0982026-B1 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | claimed |
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-25 | — | — | US | claimed |
| US-6184236-B1 | Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative | HOFFMANN-LA ROCHE INC. | 2001-02-06 | — | — | US | claimed |
| EP-0982026-A2 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-01 | — | — | EP | claimed |
| EP-0982026-B1 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-6919377-B2 | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists | WARNER LAMBERT COMPANY LLC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-25 | — | — | US | disclosed |
| CN-1441773-A | Cyclohexylamine derivative as subtype selective NMDA receptor Antagonists | WARNER LAMBERT CO (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1278716-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001081295-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| US-6184236-B1 | Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative | HOFFMANN-LA ROCHE INC. | 2001-02-06 | — | — | US | disclosed |
| EP-0982026-A2 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | GRIN1, GRIN2A, GRIN2B | KDM4E 3223/4885SLC18A3 269/4885GRIN2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.